Scope, Claims, and US Patent Landscape for U.S. Patent 5,968,895

U.S. Patent 5,968,895 claims a solid ionic complex formed between an LHRH analogue (or other pharmaceutically active peptide) and a carrier macromolecule, with a defined carrier:peptide (or carrier:analogue) weight ratio range of 0.5:1 to 0.1:1, and an explicit exclusion that the complex “is not a microcapsule.” The scope is structured around (i) complex formation parameters and (ii) sustained delivery duration thresholds (≥1 week through ≥4 weeks).

The claims define a broad peptide class (including LHRH analogues/antagonists and other peptide hormones/analogues), and a defined set of anionic carrier polymers and derivatives (with multiple representative examples plus a closed “selected from” list for specific carriers). The practical commercial focus is long-acting, depot-like dosing without microcapsule architecture.

What does U.S. 5,968,895 claim, in plain technical scope terms?

Core independent claim 1 (LHRH analogue + carrier macromolecule ionic complex)

Claim 1 covers:

Product form: “a pharmaceutical composition comprising a solid ionic complex”
Actives: an LHRH analogue
Carrier: a “carrier macromolecule”
Stoichiometry window: carrier:analogue 0.5:1 to 0.1:1
Architecture exclusion: complex is not a microcapsule
No explicit polymer identity constraint in claim 1 (polymer specifics appear in dependent claims)

Independent claim 10 (broad peptide + carrier macromolecule ionic complex)

Claim 10 covers:

“a pharmaceutical composition consisting essentially of a solid ionic complex”
“a pharmaceutically active peptide” and a “carrier macromolecule”
carrier:peptide 0.5:1 to 0.1:1
complex not a microcapsule

“Consisting essentially of” narrows to compositions that do not materially change the essential ionic-complex character, while still allowing minor excipients consistent with a solid ionic complex depot.

Dependent claims define sustained delivery and peptide/carrier sub-classes

Claims 2-5 and 12-15 create duration tiers: sustained delivery for at least 1, 2, 3, or 4 weeks after administration.
Claims 6-9 and 16-19 constrain peptide charge class and size:
- multivalent cationic or anionic peptides
- peptide lengths: 5-20, 8-15, 8-12 amino acids
Claims 20-24 specify carrier types:
- anionic polymers
- anionic polyalcohol derivatives or fragments/derivatives
- anionic polysaccharide derivatives or fragments/derivatives
- exemplars: carboxymethylcellulose
- a closed list of specific carriers: algin, alginate, anionic acetate polymers, anionic acrylic polymers, xantham gums, anionic carageenan derivatives, anionic polygalacturonic acid derivatives, sodium starch glycolate, and fragments/derivatives/salts thereof
Claim 25 allows lyophilized solid dosage form.
Claim 26 allows post-processing into suspensions or semi-solid dispersions while maintaining the ionic complex identity (claim language focuses on how the solid ionic complex is presented).
Claims 27-31 focus on specific LHRH antagonists with explicit structural elements, and claim 32 expands to other peptide actives.

How do the individual claim elements narrow or broaden coverage?

1) The ionic complex is the defining structural element

Both independent claims require:

solid ionic complex
formed between peptide/analogue and carrier macromolecule
within a carrier:peptide weight ratio window (0.5:1 to 0.1:1)
and not microcapsules

This implies that even if a product provides sustained release, it can still fall outside coverage if it does not meet the solid ionic complex definition or meets the product architecture via microcapsules.

2) The carrier:peptide ratio window is material and measurable

All core independent claims include:

carrier:analogue (claim 1): 0.5:1 to 0.1:1
carrier:peptide (claim 10): 0.5:1 to 0.1:1

Practically, this is a scope gate for formulation composition. Variants that use a substantially higher carrier fraction (above 0.5:1) or lower fraction (below 0.1:1) are outside these independent claim ranges.

3) “Sustained delivery” ties to functional outcome durations

The duration tiers (≥1 week, ≥2 weeks, ≥3 weeks, ≥4 weeks) sit as dependent claims:

Claim 2: ≥1 week
Claim 3: ≥2 weeks
Claim 4: ≥3 weeks
Claim 5: ≥4 weeks
(and parallel set for claim 10: claims 12-15)

This allows a competitor to potentially avoid a specific dependent claim by achieving a shorter release profile, while still infringing independent claim 1/10 if the product still is a solid ionic complex and meets the ratio and microcapsule exclusion. Conversely, proving the duration performance can be an enforcement lever.

4) Charge and length constraints apply mainly to dependent claims

For peptide-specific dependent coverage:

Claim 6/16: “multivalent cationic or anionic peptide”
Claim 7/17: 5-20 amino acids
Claim 8/18: 8-15 amino acids
Claim 9/19: 8-12 amino acids

If an accused peptide falls outside those ranges (for instance >20 amino acids), infringement depends on whether independent claims 1/10 are still met (they do not impose peptide length/charge constraints explicitly). The dependent claims increase coverage probability for common short LHRH analogues and peptides.

5) Carrier identity constraints are only imposed in dependent claims

Claim 1 and claim 10 do not list specific carriers, so generic anionic carrier macromolecules may still fall within claim 1/10 so long as they form the required ionic complex and ratio.

Dependent claims 20-24 impose specific carrier character and/or enumerated lists:

claim 20: anionic polymer
claim 21-22: anionic polyalcohol or polysaccharide derivatives (or fragments/salts)
claim 23: specifically carboxymethylcellulose and fragments/derivatives
claim 24: a closed list includes algin/alginates, anionic acetate/acrylic polymers, xantham gums, anionic carageenan derivatives, anionic polygalacturonic acid derivatives, sodium starch glycolate, plus fragments/derivatives/salts

That creates a clearer infringement path for formulations built on common anionic polysaccharide depots.

Where are the “hot spots” in the claim set?

LHRH antagonists with explicit sequence/structure (claims 27-31)

These claims anchor the landscape to known LHRH antagonist scaffolds. The key narrowing is the explicit structure definition. Coverage becomes strong when a marketed candidate uses that exact antagonist sequence/structure.

Claim 27: active peptide is an LHRH analogue
Claim 28: specifically an LHRH antagonist
Claim 29: an antagonist where a residue corresponding to position 6 includes “a D-asparagine structure”
Claim 30: antagonist specified by a structure formula A-J with explicit allowed residues at each position
Claim 31: antagonist with the explicit peptide sequence:
- Ac-D-Nal-4-Cl-D-Phe-D-Pal-Ser-N-Me-Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala

This set creates a “pin” for certain antagonist embodiments rather than generic LHRH analogues.

Carrier examples match long-acting peptide depot materials

The carrier list in claim 24 points to polymers and derivatives commonly used to form sustained-release or depot formulations:

alginates/algin
acrylic and acetate anionic polymers
xantham gum
anionic carageenan derivatives
anionic polygalacturonic acid derivatives
sodium starch glycolate
fragments/derivatives/salts

If an accused formulation uses one of these carriers as the ionic complex partner in the specified carrier:peptide ratio, the claim coverage tightens.

Microcapsule exclusion (all key independent claims)

“All the action, none of the microcapsules” is explicit:

claim 1: complex is not a microcapsule
claim 10: complex is not a microcapsule

This is a potential design-around point for depot products built on microcapsule architectures (even if sustained release is achieved). If a competitor uses a microcapsule depot, it may avoid these claims even with identical peptides and carriers, assuming the complex is microcapsular as such.

How does “consisting essentially of” affect infringement risk (Claim 10)?

Claim 10 is narrower than a purely “comprising” claim. “Consisting essentially of” generally means the formulation can include compatible excipients that do not materially alter the essential characteristics. Here, the essential characteristic is the solid ionic complex at the specified ratio, non-microcapsule architecture, and the sustained delivery functional property in dependent tiers.

Business implication: generic formulation fillers are likely permissible, but major changes to the depot mechanism (for example, switching from ionic complex to covalent conjugate, particulate matrix, or microencapsulation) could argue outside scope.

What does the claim map imply about the likely competitive set?

Covered therapeutic objective

The claims are aimed at depot-like sustained release for:

LHRH agonists/antagonists, especially antagonists with explicit structural motifs
other peptide hormones and analogues listed in claim 32:
- bradykinin analogues
- parathyroid hormone
- adenocorticotrophic hormone
- calcitonin
- vasopressin analogues

So the landscape is not limited to endocrine oncology or reproductive medicine; it extends to peptide peptide hormone classes where sustained release is a common development goal.

Likely infringement vectors

A competitor is within the claim frame if it:

formulates a solid ionic complex of the peptide/analogue plus an anionic carrier macromolecule
uses the carrier:peptide ratio 0.5:1 to 0.1:1
ensures the composition is not microcapsular
achieves sustained release thresholds matching the dependent claims (if those tiers are asserted)

Likely design-around vectors

A competitor can attempt to avoid the patent by:

using a carrier:peptide ratio outside 0.5:1 to 0.1:1
using a product architecture that is microcapsular rather than “solid ionic complex” (depending on claim construction)
changing the release mechanism away from ionic complex so that the product is not the claimed “solid ionic complex”
achieving shorter release than the dependent sustained duration thresholds (if only dependent claims are asserted)

What is the claim-by-claim scope matrix (elements and narrowing points)?

Claim	Main subject	Actives	Carrier requirement	Ratio	Non-microcapsule	Sustained delivery threshold
1	Composition of solid ionic complex	LHRH analogue	Carrier macromolecule (not limited here)	0.5:1 to 0.1:1	Yes	Not specified in claim 1
2	Dependent on 1	LHRH analogue	Same as claim 1	Same	Yes	≥1 week
3	Dependent on 1	LHRH analogue	Same as claim 1	Same	Yes	≥2 weeks
4	Dependent on 1	LHRH analogue	Same as claim 1	Same	Yes	≥3 weeks
5	Dependent on 1	LHRH analogue	Same as claim 1	Same	Yes	≥4 weeks
6	Dependent on 1	LHRH analogue as multivalent peptide	Same	Same	Yes	Not specified
7-9	Dependent on 1	LHRH analogue length constrained	Same	Same	Yes	Not specified
10	Composition consisting essentially of solid ionic complex	Pharmaceutically active peptide	Carrier macromolecule	0.5:1 to 0.1:1	Yes	Not specified in claim 10
11-15	Dependent on 10	Pharmaceutically active peptide	Includes cationic peptide/anionic carrier in 11	Same	Yes	≥1 to ≥4 weeks
16-19	Dependent on 10	Multivalent peptide and length	Same	Same	Yes	Not specified
20-24	Dependent on 1/10	Same	Anionic polymer; anionic polyalcohol or polysaccharide derivatives; specific examples including CMC and enumerated polysaccharides/polymers	Same	Yes	Not specified
25	Dependent on 1/10	Same	Any within prior dependent constraints	Same	Yes	Not specified
26	Dependent on 1/10	Same	Any within prior dependent constraints	Same	Yes	Not specified
27-31	Dependent on 1/10 via LHRH analogue	LHRH antagonist including specific D-asn position and explicit sequence	Any within carrier macromolecule concept; further carrier limits only if earlier dependent claims apply	Same	Yes	Not specified unless combined with 12-15
32	Dependent on 1/10	Bradykinin analogues, PTH, ACTH, calcitonin, vasopressin analogues	Any within carrier macromolecule concept	Same	Yes	Not specified

US patent landscape: what the existing claims are positioned to block

The landscape assessment must be tied to the claim architecture in 5,968,895: ionic complex solid depots for sustained delivery, with a particular ratio range and microcapsule exclusion. On that basis, the primary competitive threats are patents that claim:

long-acting peptide depots that use ionic complexation between peptide and polymer (especially anionic polysaccharides like alginate or carboxymethylcellulose) and that package the solid complex into injectable depot forms (lyophilized solids, suspensions, or semi-solid dispersions)
sustained-release peptide systems that achieve week-level delivery without microencapsulation architecture

The secondary threat is patents that use the same LHRH antagonist sequences/structures (or close variants that still meet the structural formula/sequence constraints).

The key point for portfolio strategy: 5,968,895 is positioned as a formulation-mechanism patent (ionic complex + polymer carrier + ratio + non-microcapsule architecture) rather than a purely peptide-structure patent. The LHRH antagonist sequence claims (29-31) extend enforceability specifically into particular antagonist embodiments, while the peptide class language and carrier list extend the formulation hook across multiple peptide therapeutics.

Operational implications for R&D and freedom-to-operate analysis

1) Formulation choices likely to be most scrutinized

The carrier:peptide ratio being within 0.5:1 to 0.1:1
Whether the depot actually is a solid ionic complex rather than another solid dispersion mechanism
Whether the product is microcapsule (particle-by-particle microencapsulation) versus a solid ionic complex that is dispersed/suspended for injection
Whether the observed in vivo release meets ≥1/2/3/4-week thresholds

2) How to interpret “not a microcapsule”

This is a scope limiter. It likely requires the accused depot to avoid microencapsulated architecture. If a competitor uses a polymer blend that forms ionic complexes but also uses microcapsule fabrication, litigation will turn on whether the product is still “said complex” and whether the complex can be characterized as microcapsular.

3) LHRH antagonist sequence coverage is narrow but enforceable

If the antagonist peptide matches the explicit structure in claim 31 or meets the constraints in claim 30, claim scope tightens. If the antagonist differs (residue replacements outside the listed options), independent coverage still may exist via claims 1/10 depending on how “LHRH analogue” is interpreted, but enforcement strength against LHRH-specific dependent claims decreases.

Key Takeaways

U.S. 5,968,895 claims a solid ionic complex depot between a peptide (LHRH analogue or other peptide hormones) and an anionic carrier macromolecule, with carrier:peptide ratio 0.5:1 to 0.1:1 and an express exclusion that the complex is not a microcapsule.
The sustained-release scope is tiered: dependent claims require delivery lasting at least 1, 2, 3, or 4 weeks.
Carrier scope broadens through dependent claims but includes specific polymers and derivatives, including carboxymethylcellulose and a closed list containing algin/alginates, anionic acetate/acrylic polymers, xantham gums, anionic carageenan derivatives, anionic polygalacturonic acid derivatives, and sodium starch glycolate.
LHRH antagonist coverage becomes highly specific in claims 29-31 via explicit structural constraints and the explicit peptide sequence.
The enforceable competitive perimeter centers on ionic complex formulation with the specified ratio and non-microcapsule architecture, with additional potency for products meeting the week-level release thresholds and the explicit LHRH antagonist structures.

FAQs

Does the patent require a specific carrier identity in the independent claims?
No. Claim 1 and claim 10 require a “carrier macromolecule” but do not list specific carriers in the independent claims. Specific carrier identities appear in dependent claims 20-24.
Can a competitor infringe claim 1 without matching the sustained delivery time thresholds?
Yes in principle. Claims 2-5 add sustained delivery duration as dependent features. Claim 1 itself does not require a minimum duration; it requires the solid ionic complex structure, ratio range, and non-microcapsule limitation.
What is the ratio window that triggers independent claim coverage?
The claims require carrier:peptide (or carrier:analogue) of 0.5:1 to 0.1:1.
Is microencapsulation allowed?
The complex must be “not a microcapsule.” The patent’s scope excludes microcapsule architecture in the claimed complex.
Which LHRH antagonist coverage is the most specific?
Claims 30 and 31 specify a detailed residue-based structure formula and an explicit peptide sequence for an LHRH antagonist, including the D-asparagine feature.

References

[1] United States Patent 5,968,895, “Pharmaceutical compositions comprising solid ionic complexes,” claims 1-32 (as provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	010351	⤷ Start Trial
Austria	378059	⤷ Start Trial
Austria	383165	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,968,895

Summary for Patent: 5,968,895